Stocks · Healthcare · Biotechnology
Voyager Therapeutics, Inc. VYGR
$2.45 -8.58% Close, Oct 2, 2026 · NASDAQ · Market cap $148.0M
Weak trendExpensive vs sector
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -340.1% from -289.8% a year earlier.
- Over the past year the stock returned -47.6%, behind the S&P 500 by 62.7 percentage points.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 15%
- Revenue growth, 3-year CAGRBottom 22%
- Revenue growth accelerationTop 7%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 20%
- Gross marginBottom 6%
- Operating marginBottom 19%
- Accruals (lower is better)Bottom 10%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 10%
- Free-cash-flow yieldBottom 4%
- EBITDA / enterprise valueBottom 7%
- Sales / enterprise valueTop 48%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 20%
- 6-month returnBottom 10%
- 1-year return vs S&P 500Bottom 11%
- Distance from 52-week highBottom 21%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 32%
- Consecutive EPS beatsTop 19%
- Share of analysts rating BuyTop 43%
- Upside to consensus price targetTop 4%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 37%
- Maximum drawdown, 3 yearsBottom 39%
- Beta vs S&P 500 (lower is better)Bottom 34%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -45.5% | -19.1% | ↑ |
| Gross margin | -195.7% | -104.2% | ↑ |
| Operating margin | -289.8% | -340.1% | ↓ |
| FCF margin | -272.0% | -352.4% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -19.1% | -45.5% | ↑ | Bottom 15% |
| Gross margin | -104.2% | -195.7% | ↑ | Bottom 6% |
| Operating margin | -340.1% | -289.8% | ↓ | Bottom 19% |
| Net margin | -312.6% | -253.5% | ↓ | — |
| Free-cash-flow margin | -352.4% | -272.0% | ↓ | — |
| Return on invested capital | -62.4% | — | Bottom 20% | |
| Revenue growth, 3-year CAGR | -0.4% | — | Bottom 22% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 6.5%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 34.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +44.0 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -4.36%
- Shareholder yield
- -4.36%
- Share count change, 1 year
- +3.2%
- Share count change, 3-year CAGR
- +11.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 4
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +14.1%
- Average 2-day reaction, last 8
- -1.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $14.40
- Target vs current price
- +487.8%
- Analysts with a rating
- 21
- Share rating Buy or Strong Buy
- 81%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +17.3% | +1.0% | +3.2% | +14.2% | — |
| May 7, 2026 | +13.0% | -5.0% | -0.5% | -13.2% | -28.1% |
| Mar 9, 2026 | +14.8% | +5.4% | +14.4% | +1.8% | -7.9% |
| Nov 10, 2025 | +11.3% | +0.7% | -7.1% | +2.1% | -16.3% |
| Aug 6, 2025 | -18.7% | +0.6% | +0.3% | +8.9% | +36.4% |
| May 6, 2025 | -51.4% | -6.9% | -4.0% | -6.0% | -8.6% |
| Mar 11, 2025 | -68.6% | -4.8% | -6.7% | -26.6% | -20.4% |
| Nov 12, 2024 | +64.4% | -2.6% | -23.1% | -11.7% | -24.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.40 | -$0.48 | +17.3% | $3.2M |
| May 7, 2026 | -$0.47 | -$0.54 | +13.0% | $2.6M |
| Mar 9, 2026 | -$0.46 | -$0.54 | +14.8% | $15.3M |
| Nov 10, 2025 | -$0.47 | -$0.53 | +11.3% | $13.4M |
| Aug 6, 2025 | -$0.57 | -$0.48 | -18.7% | $5.2M |
| May 6, 2025 | -$0.53 | -$0.35 | -51.4% | $6.5M |
| Mar 11, 2025 | -$0.59 | -$0.35 | -68.6% | $6.3M |
| Nov 12, 2024 | -$0.16 | -$0.45 | +64.4% | $24.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 4.20× | — | — | Top 48% |
| Free-cash-flow yield | -82.02% | — | — | Bottom 4% |
| Earnings yield | -73.88% | — | — | Bottom 10% |
P/E over the past five years
Range 2.9× – 29.3× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -5.0%
- 200-day average slope (20 days)
- -3.2%
- Distance from 50-day average
- -22.3%
- Distance from 200-day average
- -33.0%
- RSI (14)
- 23.3
- Relative volume
- 2.16×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 48.6%
- Volatility vs own 5-year history
- 12th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.42
- Correlation with S&P 500
- 0.33
- Current drawdown from 1-year high
- -54.0%
- Maximum drawdown, 3 years
- -77.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jun 20, 2023 | Oct 2, 2026 | -82.5% | 825 days | Not yet recovered |
| Oct 16, 2020 | Oct 5, 2021 | -79.9% | 243 days | 408 days (May 19, 2023) |
| May 22, 2023 | Jun 2, 2023 | -18.0% | 8 days | 11 days (Jun 20, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $148.0M
- EPS, diluted (TTM)
- -$1.81
- Revenue (TTM)
- $34.5M
- 52-week range
- $2.42 – $5.55
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $37.4M | $40.9M | $250.0M | $80.0M | $40.4M |
| Gross profit | -$36.4M | -$14.9M | $157.8M | $80.0M | -$91.9M |
| Operating income | -$73.6M | -$50.8M | $122.0M | -$83.3M | -$131.8M |
| Net income | -$71.2M | -$46.4M | $132.3M | -$65.0M | -$119.7M |
| EPS (diluted) | -$1.75 | -$1.21 | $2.97 | -$1.13 | -$2.04 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $24.6M | $6.3M | $6.5M | $5.2M | $13.4M | $15.3M | $2.6M | $3.2M |
| Net income | -$9.0M | -$34.5M | -$31.0M | -$33.4M | -$27.9M | -$27.4M | -$27.9M | -$24.5M |
| EPS (diluted) | -$0.16 | -$0.59 | -$0.53 | -$0.57 | -$0.47 | -$0.47 | -$0.47 | -$0.40 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$53.5M | -$12.5M | $77.9M | -$15.3M | -$132.5M |
| Capital expenditure | -$1.6M | -$2.5M | -$3.3M | -$3.5M | -$2.6M |
| Free cash flow | -$55.1M | -$15.0M | $74.7M | -$18.8M | -$135.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $612,000 | $1.1M | $33.6M | $114.0M | $816,000 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $116.3M
- Total assets
- $197.8M
- Total liabilities
- $43.4M
- Total debt
- $32.6M
- Net debt
- -$3.2M
- Shareholders’ equity
- $154.4M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 3,655,802
- Days to cover
- 8.61
- Change vs previous report
- -3.4%
FINRA short interest, settlement date Sep 15, 2026.